Fingolimod Therapy in Multiple Sclerosis Leads to the Enrichment of a Subpopulation of Aged NK Cells

Fingolimod is an approved oral treatment for relapsing–remitting multiple sclerosis (RRMS) that modulates agonistically the sphingosin-1-phosphate receptor (S1PR), inhibiting thereby the egress of lymphocytes from the lymph nodes. In this interventional prospective clinical phase IV trial, we longit...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwichtenberg, Svenja C., Wisgalla, Anne, Schroeder-Castagno, Maria, Alvarez-González, Cesar, Schlickeiser, Stephan, Siebert, Nadja, Bellmann-Strobl, Judith, Wernecke, Klaus-Dieter, Paul, Friedemann, Dörr, Jan, Infante-Duarte, Carmen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8608997/
https://www.ncbi.nlm.nih.gov/pubmed/34244929
http://dx.doi.org/10.1007/s13311-021-01078-7

Ejemplares similares

Ejemplares similares